Valvular heart disease and the use of dopamine agonists for Parkinson's disease

New England Journal of Medicine

Volumn 356, Issue 1, 2007, Pages 39-46

  Zanettini, Renzo ^a   Antonini, Angelo ^a   Gatto, Gemma ^a   Gentile, Rosa ^a   Tesei, Silvana ^a   Pezzoli, Gianni ^a  

^a PARKINSON INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; AORTA VALVE REGURGITATION; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRICUSPID VALVE REGURGITATION;

EID: 33845974147     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa054830     Document Type: Article

References (19)

1. Flowers CM, Racoosin JA, Lu SI, Beitz JG. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730-1.
2. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003;61:859-61.
3. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-83.
4. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004;63:301-4.
5. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-62.
6. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005;353:1976-7.
7. Serratrice J, Disdier P, Habib G, Viallet F, Weiller P. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 2002;10:334-6.
8. Rascol O, Pathak A, Bagheri H, Montastruc JL. New concerns about old drugs: valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord 2004;19:611-3.
9. Chaudhuri KR, Dhavan V, Basu S, Jackson G, Odin P. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord 2004;19:1522-3.
10. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-2.
11. Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999;100:2161-7.
12. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101:2071-7.
13. Botero M, Fuchs R, Paulus DA, Lind DS. Carcinoid heart disease: a case report and literature review. J Clin Anesth 2002;14:57-63.
14. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-41.
15. Jahnichen S, Horowski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 2005;513:225-8.
16. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777-802.
17. Lancellotti P, Lebrun F, Pierard LA. Determinants of exercise-induced changes in mitral regurgitation in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2003;42:1921-8.
18. Srichai MB, Grimm RA, Stillman AE, et al. Ischaemic mitral regurgitation: impact of the left ventricle and mitral valve in patients with left ventricular systolic dysfunction. Ann Thorac Surg 2005;80:170-8.
19. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657-62.